DA
TEVA icon

Duality Advisers’s Teva Pharmaceuticals TEVA Stock Holding History

Duality Advisers’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-155,267
Closed -$1.62M – 745
2023
Q4 		$1.62M Buy
+155,267
New +$1.45M 0.17% 219
2023
Q3 		– Sell
-316,056
Closed -$2.38M – 713
2023
Q2 		$2.38M Buy
316,056
+20,891
+7% +$169K 0.3% 123
2023
Q1 		$2.61M Buy
+295,165
New +$2.92M 0.3% 131
2022
Q4 		– Sell
-350,417
Closed -$2.83M – 774
2022
Q3 		$2.83M Sell
350,417
-27,619
-7% -$244K 0.31% 106
2022
Q2 		$2.84M Buy
+378,036
New +$3.29M 0.28% 124

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Duality Advisers's TEVA Position: Q1 2024 in Review

Duality Advisers sold out of Teva Pharmaceuticals (TEVA) in Q1 2024, closing a stake of 155,267 shares — an estimated $1.62M sold.

Duality Advisers first reported a position in TEVA in Q2 2022 and held it in 5 quarters. The position peaked at $2.84M in Q2 2022. 481 funds tracked by Wall St. Rank hold TEVA as of Q1 2024.

  • Duality Advisers reported no remaining Teva Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Duality Advisers sold 155,267 Teva Pharmaceuticals shares in Q1 2024, an estimated $1.62M.
  • Duality Advisers first reported a position in Teva Pharmaceuticals in Q2 2022 and held it in 5 quarters.
  • Duality Advisers's Teva Pharmaceuticals position peaked at $2.84M in Q2 2022.
  • 481 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2024.

Based on Duality Advisers's 13F filing for Q1 2024, filed 6 May 2024.